AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01494285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARK-E021 10%
Description: Topically applied once daily at bedtime
Study NCT01494285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topically applied once daily at bedtime
Study NCT02441452 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early rehabilitation
Description: The physical exercises and breathing exercises are started as soon as after the Nuss procedure
Study NCT03895060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autogenous ring blockls with GBR covered by collagen membrane
Description: * A crestal incision is made using No. 15 blade extending over the anterior maxilla, an anterior vertical releasing incision is made and a full mucoperiosteum flaps elevated to provide access to the alveolar ridge and the lateral aspect of the maxilla~* Autogenous onlay ring blocks is taken by a trephine bur from the chin area and then fixed by screws to the deficient maxillary alveolar height.~* Equally autogenous and xenograft bone particles is packed around the screw to fill the defect area completely.~* The collagen membrane is fixed to the alveolar ridge by bone tacks and the mixture of autogenous and xenograft bone is then packed.~* The flap will then be closed using interrupted 4/0 resorbable sutures.
Study NCT04231630 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prolacta
Description: Will receive outpatient supplementation with donor human milk product added to mother's own milk
Study NCT00443547 — intervention group
Intervention type: DEVICE
Intervention: Vectra-T
Description: Patient will receive the Vectra-T plate (Sized 1 to 4 levels)
Study NCT00983229 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation
Description: Insertion of a plastic tube under direct vision (built-in camera, intubating fibrescope) into trachea.
Study NCT03067441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bempedoic acid
Description: bempedoic acid 180 mg tablets taken orally, once per day.
Study NCT03814447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti- MESO CAR-T cells
Description: Autologous genetically modified anti- MESO CAR transduced T cells
Study NCT03814447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Dose: 30mg/m2/d
Study NCT03814447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Dose: 300mg/m2/d
Study NCT02163031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: devices used in the coronary angiography
Description: devices used in coronary angiography by left or right radial route
Study NCT01226654 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging EDSS
Study NCT03564509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999302 (1 μg) and follitropin delta
Description: Daily dose of 1 μg of FE 999302, a recombinant human chorionic gonadotropin (rhCG) solution for subcutaneous injection; individualized follitropin delta dose.
Study NCT03564509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999302 (2 μg) and follitropin delta
Description: Daily dose of 2 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
Study NCT03564509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999302 (4 μg) and follitropin delta
Description: Daily dose of 4 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
Study NCT03564509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999302 (8 μg) and follitropin delta
Description: Daily dose of 8 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
Study NCT01465490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitoring and Feedback Intervention
Description: Clients participate in standard treatment and complete the MMI weekly with their counselors at the beginning of each individual counseling session. Counselors have been trained to administer the MMI and will have access to the data to use during sessions.
Study NCT02066935 — intervention group
Intervention type: OTHER
Intervention: kidney transplant patient
Description: kidney transplanted patients for at least one year
Study NCT06535217 — intervention group
Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Liver transplantation
Study NCT03866174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.
Study NCT03866174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacin
Description: The active placebo is encapsulated using a HPMC capsule and contains 100 mg of pharmaceutical grade niacin.
Study NCT03866174 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Set and Setting (SaS) Protocol
Description: The SaS Protocol prescribes 6-8 hours of preparatory meetings with two facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two facilitators, and 4 hours of post-dose integration sessions with facilitators. During the dosing session participants are encouraged to wear eyeshades and listen to a curated playlist on headphones.
Study NCT03866174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Set and Setting (SaS) Protocol
Description: The SaS Protocol prescribes 6-8 hours of preparatory meetings with two facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two facilitators, and 4 hours of post-dose integration sessions with facilitators. During the dosing session participants are encouraged to wear eyeshades and listen to a curated playlist on headphones.
Study NCT02921412 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fanfilcon A
Description: contact lens
Study NCT02291718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isovue
Description: iodine contrast
Study NCT02806739 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Group (Soy Protein + Isoflavones)
Description: Women in the intervention group are asked to eat a combination of soy foods that contain about 25 grams of protein and 60-75 milligrams of isoflavones per day, from the 16th gestational week to birth. A registered dietitian will instruct them to incorporate the soy foods into their daily diet.
Study NCT02806739 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Group (Minimize Soy Intake)
Description: Women in the control group will be instructed by the dietitian how to avoid soy supplements and minimize soy intake.
Study NCT00882674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: 16mg/kg, 9mg/kg, 3mg/kg or 1mg/kg iv on Day 1 in one of 4 cohorts of patients
Study NCT01564225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDI200
Description: Cohort 1 will be dosed at 3 mg/kg/dose. Cohort 2 will be dosed at 10 mg/kg/dose. Both cohorts will receive 2 doses/week for a total of 5 doses.
Study NCT02842567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol plus Vitamin E
Description: This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks
Study NCT03613571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILB
Description: The investigational medicinal product ILB will be given as single short-term s.c. injections in the abdomen, the thigh or the buttock, in that order of priority. Subjects will be observed for at least 3 hours after injection.The IMP is a sterile, colourless to pale yellow solution for subcutaneous injection.
Study NCT00521807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: a standardized hypnosis treatment with ten consecutive therapeutic sessions once a week,
Study NCT02842567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will treated with 2 identical placebo pills daily given orally for 16 weeks.
Study NCT00395044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00395044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Study NCT03906058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: All patients enrolled in the study will accept anlotinib treatment as a palliative treatment .
Study NCT00987207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A
Description: a single bolus of 2.5 mg/kg, administered before aortic cross-declamping
Study NCT00987207 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No injection
Description: No cyclosporine A is administered before aortic cross-declamping.
Study NCT02506998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DLE
Description: Adjuvant treatment
Study NCT02506998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Second generation anti histamines + Nasal corticosteroids
Description: Standard treatment
Study NCT02446041 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study NCT03564509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999302 (12 μg) and follitropin delta
Description: Daily dose of 12 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
Study NCT03564509 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and follitropin delta
Description: Daily dose of placebo; individualized follitropin delta dose.
Study NCT00591526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arac
Description: Ommit ARAC in the chemotherapy
Study NCT02426632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.
Study NCT02426632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.
Study NCT00591526 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Arac
Description: Ommit ARAC in the chemotherapy
Study NCT02426632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: 10 mg/mL oral solution containing 10 mg/mL sucralose.
Study NCT03534687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 12-week supervised aerobic exercise
Study NCT01199939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine
Description: 400mg once daily orally for 48 weeks
Study NCT01199939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100mg once daily orally for 48 weeks
Study NCT01199939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 800mg once daily orally for 48 weeks
Study NCT02896634 — intervention group
Intervention type: BIOLOGICAL
Intervention: clinical biology analyzes spectrometry mass
Description: clinical biology analyzes spectrometry mass
Study NCT02426632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.
Study NCT01973270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuroadaptive cognitive training
Description: TCT exercises consist of three modules: an Auditory Processing Module (40-50 hours of training); a Visual Processing Module (30 hours); a Cognitive Control Module prototype (20 hours). \[Based on the results of our current RCT, Posit Science has revised aspects of the training modules in order to further optimize its effectiveness for treatment of schizophrenia. In this study, we will use updated versions of the training software: an Auditory Module (20 hours), and a Social Module (10 hours). Features from the Cognitive Control module prototype have been expanded and incorporated into these new modules.
Study NCT02146235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-Music Therapy
Study NCT02517099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclometasone
Description: Beclometasone dipropionate 200mcg bd for 4 months
Study NCT02517099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-amoxiclav
Description: Co-amoxiclav 0.3ml/kg bd for 4 weeks
Study NCT02517099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin 10mg/kg od for 4 weeks
Study NCT02426632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.
Study NCT02538055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Healthy
Description: This intervention tested the effects of a community health worker delivered lifestyle modification program based on cognitive behavioral therapy on diabetes and pain outcomes in individuals with diabetes and chronic pain.
Study NCT02538055 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Health Program
Description: Participants in this arm worked with a Community Health Worker (CHW) who provided a general health program that consisted of didactic information of unrelated general health information. Participants received the same number of contacts with their CHW as the intervention arm. Participants and CHW interacted by telephone 8 times over 3 months.
Study NCT01717755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment
Description: IA therapy has to be initiated within 6 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of IA strategy wil be made by the treating neurointerventionalist. Choice of therapy depends on local approval and experience. If IA thrombolysis is the chosen strategy, a maximum of 22 mg of IA rt-PA or 1.500.000 Units of Urokinase may be given. Stenting is allowed in the presence of a high-grade vertebral artery stenosis or occlusion hampering adequate endovascular access to the basilar artery and in case of a residual high-grade basilar artery stenosis. The use of any other treatment strategy depends on local approval and experience, and is only allowed after prior approval of the steering committee.
Study NCT02426632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation F
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.
Study NCT02426632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation M1
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
Study NCT00006747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: IV
Study NCT00006747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: IV
Study NCT00006747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: IV
Study NCT00006747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: IV
Study NCT00006747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: IV
Study NCT00006747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: IV
Study NCT00006747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: IV
Study NCT00006747 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplant
Study NCT03959579 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: systematic endomyocardial biopsy.
Description: We sought to compare the long term survival of HTx recipients followed with or without systematic endomyocardial biopsy. Second, the sensibility and specificity of cardiac echo to diagnose acute allograft rejection will be analyzed.~To show the safety of non-invasively monitoring HTx recipients without systematic endomyocardial biopsy
Study NCT02260583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal CO2 device
Description: An ECCO2R device based on a modified continuous venovenous hemofiltration system will be used
Study NCT00570804 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone Counseling
Description: 7 counseling calls where quit date set on first counseling call; then counseling calls on quit date, 3-5 days after quit date, 7-10 days after quit date, 15-30 days after quit date, 45-60 days after quit date, and 90 days after quit date, each taking about 15 to 30 minutes to complete.
Study NCT00570804 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone Assessments
Description: 4 assessment telephone calls at Weeks 12, 26 and 52 (interview by a research staff member), taking about 30 minutes each to complete.
Study NCT02633345 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic tablets
Description: Tablets with both Lactobacillus rhamnosus PB01 and Lactobacillus curvatus P2-2. Two tablets a day for four weeks
Study NCT02633345 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT02426632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation M2
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
Study NCT02995265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton Program
Description: Subjects will wear the exoskeleton device at each physiotherapy session to work on improving mobility and walking ability.
Study NCT02995265 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Program
Description: Subjects will receive hands-on physiotherapy to improve their mobility and walking ability. Physiotherapy session will be tailored to subject individually by their therapist.
Study NCT00951899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Description: Colesevelam hydrochloride; three 625mg tablets taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
Study NCT00951899 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three placebo tablets matching the active drug colesevelam in appearance, taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
Study NCT00951899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Subjects were instructed to follow a weight maintenance diet (\~55% carbohydrate, 30% fat and 15% protein) for the 12 week study period.
Study NCT00951899 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diet
Description: Subjects were instructed to follow a weight maintenance diet (\~55% carbohydrate, 30% fat and 15% protein) for the 12 week study period.
Study NCT00951899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Subjects continued to take their pre-study therapeutic doses of metformin (Metformin 500mg tablets taken by mouth twice daily for a total daily dose of 1000 to 2000 mg) through the 12 week study period.
Study NCT00951899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Subjects continued to take their pre-study therapeutic doses of metformin (Metformin 500mg tablets taken by mouth twice daily for a total daily dose of 1000 to 2000 mg) through the 12 week study period.
Study NCT02426632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation M3
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
Study NCT02426632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation N1
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
Study NCT02151162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress management program
Description: Mindfulness-based stress management program will be conducted by senior nurses in four individual sessions within these three months. Senior nurses have taken a 7-hour workshop including lectures and role-playing sessions. The detailed manual and videos including lectures will be provided to the senior nurses.
Study NCT02151162 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based stress management program
Description: Mindfulness-based stress management program will be conducted by senior nurses in four individual sessions within these three months. Senior nurses have taken a 7-hour workshop including lectures and role-playing sessions. The detailed manual and videos including lectures will be provided to the senior nurses.
Study NCT02426632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation N2
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
Study NCT02426632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation N3
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).